DOK7抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Hela cell lysate, Primary antibody: P06940(DOK7 Antibody) at dilution 1/700, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 3 seconds    

  
  

DOK7 (docking protein 7) is a cytoplasmic adaptor protein crucial for the formation and maintenance of the neuromuscular junction (NMJ). It belongs to the DOK family of signaling molecules, which mediate protein-protein interactions in tyrosine kinase pathways. DOK7 is specifically involved in the activation of muscle-specific receptor tyrosine kinase (MuSK), a key player in NMJ development. By binding to MuSK, DOK7 facilitates the assembly of the agrin-MuSK signaling complex, which drives acetylcholine receptor (AChR) clustering and synaptic differentiation.

Antibodies targeting DOK7 have gained attention in both research and clinical contexts. In research, anti-DOK7 antibodies are tools to study NMJ formation, synaptic plasticity, and related signaling pathways. Clinically, autoantibodies against DOK7 are implicated in congenital myasthenic syndromes (CMS), a group of inherited neuromuscular disorders. These autoantibodies disrupt DOK7-MuSK interactions, impairing NMJ signaling and leading to muscle weakness. Additionally, DOK7 autoantibodies are occasionally detected in seronegative myasthenia gravis patients, expanding diagnostic and therapeutic avenues.

Therapeutic strategies targeting DOK7. including antibody neutralization or gene therapy, are under exploration for CMS and other neuromuscular conditions. DOK7 antibodies thus serve as both investigative probes and potential biomarkers or therapeutic targets in neuromuscular diseases.